{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:32:55Z","timestamp":1793910775707,"version":"4.8.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["413490537"],"award-info":[{"award-number":["413490537"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejso.2025.110392","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T06:29:44Z","timestamp":1755239384000},"page":"110392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Axillary surgery in early breast cancer: real-world analysis of the INSEMA-trial at three certified university breast cancer centers in Germany regarding the omission of sentinel lymph node biopsy"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4592-2151","authenticated-orcid":false,"given":"Nikolas","family":"Tauber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4972-0177","authenticated-orcid":false,"given":"Anna-Christina","family":"Rambow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Gasthaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Fick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Grande-Nagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisbeth","family":"Hilmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Kohls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Krawczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1003-0839","authenticated-orcid":false,"given":"Huy Duc","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elessawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolai","family":"Maass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4231-7906","authenticated-orcid":false,"given":"Volkmar","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Rody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3483-8691","authenticated-orcid":false,"given":"Karl W.F.","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Schmalfeldt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Steinhilper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2374-9482","authenticated-orcid":false,"given":"Maggie","family":"Banys-Paluchowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion Tina","family":"van Mackelenbergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2025.110392_bib1","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs No axillary dissection on 10-Year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial","volume":"318","author":"Giuliano","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ejso.2025.110392_bib2","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1200\/JCO.22.01565","article-title":"Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer: 10-year results of the randomized controlled EORTC 10981-22023 AMAROS trial","volume":"41","author":"Bartels","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib3","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/GCO.0000000000000916","article-title":"Controversies in axillary management of patients with breast cancer - updates for 2024","volume":"36","author":"Tauber","year":"2024","journal-title":"Curr Opin Obstet Gynecol"},{"key":"10.1016\/j.ejso.2025.110392_bib4","article-title":"Axillary surgery in breast cancer - primary results of the INSEMA trial","author":"Reimer","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2025.110392_bib5","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jamaoncol.2023.3759","article-title":"Sentinel lymph node biopsy vs No axillary surgery in patients with small breast cancer and negative results on ultrasonography of axillary lymph nodes: the SOUND randomized clinical trial","volume":"9","author":"Gentilini","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib6","doi-asserted-by":"crossref","DOI":"10.1159\/000545019","article-title":"AGO recommendations for the diagnosis and treatment of patients with early breast cancer: Update 2025","author":"Park-Simon","year":"2025","journal-title":"Breast Care"},{"key":"10.1016\/j.ejso.2025.110392_bib7","doi-asserted-by":"crossref","DOI":"10.1007\/s00404-025-08028-0","article-title":"Therapy of early breast cancer: current status and perspectives","author":"Tauber","year":"2025","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.ejso.2025.110392_bib8","article-title":"Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update","author":"Park","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib9","volume":"5","year":"2025"},{"key":"10.1016\/j.ejso.2025.110392_bib10","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2025.110392_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216366","article-title":"The clinical relevance of the NATALEE study: application of the NATALEE criteria to a real-world cohort from two large German breast cancer centers","volume":"24","author":"Sch\u00e4ffler","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ejso.2025.110392_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17010145","article-title":"Oral maintenance therapy in early breast cancer-how many patients are potential candidates?","volume":"17","author":"Tauber","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejso.2025.110392_bib13","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO guidance for reporting oncology real-world evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib14","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib15","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-Mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2025.110392_bib16","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib17","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.23.01994","volume":"42","author":"Rastogi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.annonc.2024.10.015","article-title":"A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial","volume":"36","author":"Hortobagyi","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib19","first-page":"647","article-title":"Initial cancer treatment in certified versus non-certified hospitals","volume":"120","author":"Schmitt","year":"2023","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.ejso.2025.110392_bib20","doi-asserted-by":"crossref","first-page":"S1207","DOI":"10.1016\/j.annonc.2024.08.2251","article-title":"LBA13 adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+\/HER2\u2212 early breast cancer (EBC): 4-year outcomes from the NATALEE trial","volume":"35","author":"Fasching","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/BF02967572","article-title":"Prognostic and predictive factors in the adjuvant treatment of breast cancer","volume":"9","author":"Fukutomi","year":"2002","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejso.2025.110392_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000499931","article-title":"St. gallen\/vienna 2019: a brief summary of the consensus discussion on the optimal primary breast cancer treatment","volume":"14","author":"Balic","year":"2019","journal-title":"Breast Care"},{"key":"10.1016\/j.ejso.2025.110392_bib23","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/annonc\/mdv221","article-title":"Tailoring therapies--improving the management of early breast cancer: St gallen international expert consensus on the primary therapy of early breast cancer 2015","volume":"26","author":"Coates","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12123698","article-title":"Avoiding axillary sentinel lymph node biopsy after neoadjuvant systemic therapy in breast cancer: rationale for the prospective, multicentric EUBREAST-01 trial","volume":"12","author":"Reimer","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejso.2025.110392_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1200\/JCO.2005.01.5784","article-title":"Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of international breast cancer study group trial 10-93","volume":"24","author":"Rudenstam","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib26","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/cncr.28499","article-title":"Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09\/98)","volume":"120","author":"Agresti","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2025.110392_bib27","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(23)00051-7","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","volume":"24","author":"Tolaney","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10549-020-05842-9","article-title":"Axillary lymph node and non-sentinel lymph node metastasis among the ACOSOG Z0011 eligible breast cancer patients with invasive ductal, invasive lobular, or other histological special types: a multi-institutional retrospective analysis","volume":"184","author":"Gao","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ejso.2025.110392_bib29","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12957-024-03375-9","article-title":"Correlation between sentinel lymph node biopsy and non-sentinel lymph node metastasis in patients with cN0 breast carcinoma: comparison of invasive ductal carcinoma and invasive lobular carcinoma","volume":"22","author":"Cipolla","year":"2024","journal-title":"World J Surg Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib30","doi-asserted-by":"crossref","first-page":"e1367","DOI":"10.1016\/j.clbc.2018.07.017","article-title":"Unifocal invasive lobular carcinoma: tumor size concordance between preoperative ultrasound imaging and postoperative pathology","volume":"18","author":"Vijayaraghavan","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ejso.2025.110392_bib31","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejso.2025.110392_bib32","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S1470-2045(24)00350-4","article-title":"Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4\/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial","volume":"25","author":"de Boniface","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib33","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1245\/s10434-022-13064-0","article-title":"Delayed sentinel lymph node dissection in patients with a preoperative diagnosis of ductal cancer in situ by preoperative injection with superparamagnetic iron oxide (SPIO) nanoparticles: the SentiNot study","volume":"30","author":"Karakatsanis","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib34","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1200\/JCO.20.00650","article-title":"Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: long-term results of the randomized phase III APBI-IMRT-Florence trial","volume":"38","author":"Meattini","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib35","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.breast.2017.12.014","article-title":"Partial breast irradiation: the time is there","volume":"38","author":"Meattini","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.ejso.2025.110392_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104523","article-title":"Partial breast irradiation after sentinel lymph node biopsy omission: is it a valid alternative to whole breast irradiation? Analysis of the dose to the sentinel lymph node region during whole breast irradiation vs. partial breast irradiation","volume":"82","author":"Behzadi","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.ejso.2025.110392_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110331","article-title":"Potential for omitting sentinel lymph node biopsy in patients with human epidermal growth factor receptor 2-positive or triple negative breast cancer with non-breast pCR after neoadjuvant chemotherapy","volume":"51","author":"Shin","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.109642","article-title":"Omission of axillary dissection after neoadjuvant systemic treatment in initially node-positive HER2-overexpressed and triple-negative breast cancer patients: SENATURK OTHER-NAC study","volume":"51","author":"Cab\u0131o\u011flu","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2024.108472","article-title":"Oncologic outcomes of de-escalating axillary treatment in clinically node-positive breast cancer patients treated with neoadjuvant systemic therapy \u2013 a two center cohort study","volume":"50","author":"Schipper","year":"2024","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110253","article-title":"Lost axillary markers after neoadjuvant chemotherapy in breast cancer patients - data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655)","volume":"51","author":"Hartmann","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib41","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.ejso.2018.05.035","article-title":"Wire localization of clip-marked axillary lymph nodes in breast cancer patients treated with primary systemic therapy","volume":"44","author":"Hartmann","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110266","article-title":"Surgical MArker localization OR clip and wire application for targeted axillary dissection in node-positive breast cancer patients - results from the randomized superiority MALLORCA-Trial","volume":"51","author":"Elfgen","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2025.110392_bib43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10549-025-07635-4","article-title":"Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer-a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial","volume":"211","author":"Banys-Paluchowski","year":"2025","journal-title":"Breast Cancer Res Treat"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325008200?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325008200?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T11:47:38Z","timestamp":1772797658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325008200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0748798325008200"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110392","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Axillary surgery in early breast cancer: real-world analysis of the INSEMA-trial at three certified university breast cancer centers in Germany regarding the omission of sentinel lymph node biopsy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110392"}}